-

Labcorp First National Laboratory to Offer Monkeypox Test

Expands Access to Communities Across the United States

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced it will begin testing for monkeypox using the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects all non-smallpox related orthopoxviruses, including monkeypox. This effort is part of the Administration’s commitment to quickly increase monkeypox testing access and capacity in every community during the ongoing outbreak.

Labcorp is the first national laboratory to offer this polymerase chain reaction (PCR) test, which it verified for the CDC, and the first to launch a more automated assay option.

“Labcorp appreciates the opportunity to support the CDC in its efforts to keep the public safe and manage the monkeypox outbreak,” said Dr. Brian Caveney, chief medical officer and President of Labcorp Diagnostics. “We will initially perform all monkeypox testing in our main North Carolina lab and have the capacity to expand to other locations nationwide should the need arise.”

Labcorp will offer the testing at its largest laboratory in the United States and has the ability to accept specimens from its customers, as well as overflow from public laboratories, from across the U.S. using its significant transportation and logistics capabilities. Eventually, Labcorp will have the ability to increase capacity up to 10,000 tests per week, which will double the current capacity provided through CDC’s Laboratory Response Network (LRN). This development will facilitate increased testing by leveraging established relationships between Labcorp and the clinics, hospitals, and health care providers it serves. Labcorp will use electronic laboratory reporting (ELR) to report results to jurisdictions as outlined in the CDC reporting guidance.

The public will go to their health care provider for sample collection and to initiate the testing process; however, health care providers can order the orthopoxvirus test from Labcorp just as they normally would order other tests. This test is currently available on the Labcorp test menu.

CDC guidance is that anyone with a rash that looks like monkeypox should talk to their health care provider, even if they don’t think they had contact with someone who has monkeypox.

Health care providers can access information on Labcorp’s test at www.labcorp.com/monkeypox. The latest CDC information on monkeypox is available at www.cdc.gov/monkeypox.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Contacts

Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com

Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com

LABORATORY CORPORATION OF AMERICA HOLDINGS

NYSE:LH
Details
Headquarters: Burlington, NC
CEO: Adam Schechter
Employees: 75,000
Organization: PUB
Revenues: $16.1 billion (2021)
Net Income: $2.37 billion (2021)

Release Versions

Contacts

Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com

Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com

More News From LABORATORY CORPORATION OF AMERICA HOLDINGS

Ovia HealthTM Expands Digital Platform Capabilities to Include Menopause Tracking

BOSTON--(BUSINESS WIRE)--Ovia Health, a trusted digital health platform for women and families, today announced the expansion of its Ovia® app, which will now allow women to track menopause symptoms and access valuable resources and support to address the transition to menopause/perimenopause. The technology is available through Ovia’s consumer application and enterprise offerings for employers and health plans. According to the National Institute on Aging (NIA), more than 1 million women trans...

Labcorp Announces 2022 Fourth Quarter and Full-Year Results

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the fourth quarter and year ended Dec. 31, 2022, full-year 2023 guidance. “We finished the year strong, with accelerated revenue growth in Diagnostics, continued strong underlying fundamentals in Drug Development and margin expansion,” said Adam Schechter, chairman and CEO of Labcorp. “In 2022, we also advanced our strategy with the announcement of the spin of our Clinical...

Labcorp Unveils New Name for Future Independent Clinical Development Business - Fortrea

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that the new company to be formed by the planned spin-off of its Clinical Development business will be known as Fortrea. Upon completion of the spin-off from Labcorp, Fortrea will operate as an independent, publicly traded global CRO that offers comprehensive drug and medical device development services. With over 19,000 people, Fortrea will provide Phase I through IV clinical trial ma...
Back to Newsroom